220 Participants Needed

Selumetinib vs. Chemotherapy for Brain Cancer

Recruiting at 136 trial locations
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Will I have to stop taking my current medications?

The trial protocol does not specify if you need to stop taking your current medications. However, you cannot be on any investigational agents or receive any prior tumor-directed therapy like chemotherapy or radiation. It's best to discuss your current medications with the trial team to ensure they don't interfere with the study.

What data supports the effectiveness of the drug Selumetinib combined with Carboplatin and Vincristine Sulfate for brain cancer?

Carboplatin has shown some effectiveness in treating brain tumors, particularly when delivered directly to the brain to bypass the blood-brain barrier, as seen in studies with high-grade gliomas and brain metastases from non-small cell lung cancer. Additionally, carboplatin is often used as an alternative to cisplatin in chemotherapy regimens for other cancers, indicating its potential utility in brain cancer treatment.12345

What safety data exists for carboplatin and vincristine in treating brain cancer?

Carboplatin can cause low blood cell counts, leading to increased risk of infection and bleeding, and may also cause vomiting. Vincristine can cause nerve damage, leading to numbness or tingling in the hands and feet. Hypersensitivity reactions to carboplatin are a concern, and some patients may experience severe allergic reactions.12678

How does the drug Selumetinib differ from other treatments for brain cancer?

Selumetinib is unique because it targets specific pathways involved in cancer cell growth, unlike traditional chemotherapy which attacks rapidly dividing cells in general. This targeted approach may offer a different side effect profile and effectiveness, especially in cases where standard chemotherapy has limited success.1291011

What is the purpose of this trial?

This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.

Research Team

PM

Peter M de Blank

Principal Investigator

Children's Oncology Group

Eligibility Criteria

This trial is for children and young adults aged 2 to 21 with low-grade glioma brain tumors without certain genetic mutations or neurofibromatosis. They should not have had previous tumor treatments except surgery, must be able to swallow capsules, and meet specific health criteria like normal organ function tests.

Inclusion Criteria

My kidney function is within the required range for my age and gender.
My low-grade glioma does not have the BRAFV600E mutation and has only been treated with surgery.
My cancer has spread or I have more than one primary low-grade glioma.
See 25 more

Exclusion Criteria

I have had issues with my retina, like detachment or vein blockage.
I have a genetic disorder linked to higher risk of heart disease.
I am not pregnant and have taken a pregnancy test if capable of becoming pregnant.
See 17 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Induction

Patients receive vincristine sulfate and carboplatin intravenously, with blood collection and MRI at baseline and end of induction

9 weeks
10 visits (in-person)

Maintenance

Patients continue receiving vincristine sulfate and carboplatin intravenously, with blood collection and MRI throughout the trial

Up to 48 weeks
4 visits per cycle (in-person), up to 8 cycles

Treatment with Selumetinib

Patients receive selumetinib sulfate orally twice daily, with blood collection and MRI throughout the trial

Up to 27 months
Monthly visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to 10 years
Every 3 months for year 1, every 6 months for years 2-3, annually for years 4-10

Treatment Details

Interventions

  • Carboplatin; Vincristine Sulfate
  • Selumetinib
Trial Overview The study compares the new drug Selumetinib against the standard chemotherapy drugs Carboplatin and Vincristine in treating low-grade gliomas. It aims to determine if Selumetinib is as effective as or better than standard treatment while also assessing its impact on quality of life.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Arm II (selumetinib sulfate)Experimental Treatment5 Interventions
Patients receive selumetinib sulfate PO BID on days 1-28. Treatment repeats every 28 days for up to 27 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and undergo MRI at baseline, throughout the trial, and during follow up.
Group II: Arm I (vincristine sulfate, carboplatin)Active Control6 Interventions
INDUCTION: Patients receive vincristine sulfate IV on days 1, 8, 15, 22, 29, 36, 43, 50, 57, and 64, and carboplatin IV over 60 minutes on days 1, 8, 15, 22, 43, 50, 57, and 64 in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and magnetic resonance imaging (MRI) at baseline and end of induction. MAINTENANCE: Patients receive vincristine sulfate IV on days 1, 8, and 15, and carboplatin IV over 60 minutes on days 1, 8, 15, and 22. Treatment repeats every 42 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and undergo MRI at baseline, throughout the trial, and during follow up.

Find a Clinic Near You

Who Is Running the Clinical Trial?

National Cancer Institute (NCI)

Lead Sponsor

Trials
14,080
Recruited
41,180,000+

Findings from Research

In a Phase I study involving 15 patients with various brain tumors, intracarotid carboplatin showed some efficacy, with one patient experiencing partial remission and others showing stable disease, although the median survival was only 9 weeks.
The treatment was associated with mild to moderate nausea and some hematological side effects, but severe complications occurred in patients with pre-existing vascular issues, highlighting the need for careful patient selection and monitoring.
Phase I study of intracarotid administration of carboplatin.Stewart, DJ., Belanger, JM., Grahovac, Z., et al.[2019]
Cisplatin, carboplatin, and oxaliplatin show limited penetration into the cerebrospinal fluid (CSF) and brain extracellular fluid (ECF), with less than 5% of plasma drug exposure reaching these areas, which may affect their efficacy in treating brain tumors.
Microdialysis revealed that while CSF concentrations of oxaliplatin were lower than those in brain ECF, the overall differences in CNS penetration among the three platinum analogs were not clinically significant, suggesting that CSF measurements can be used to estimate brain drug exposure.
Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates.Jacobs, S., McCully, CL., Murphy, RF., et al.[2021]
A Phase I clinical trial involving 10 patients with recurrent high-grade gliomas demonstrated that intracerebral convection-enhanced delivery (CED) of carboplatin is feasible and safe at doses up to 4μg over 72 hours, with only one possible adverse event reported.
The median progression-free survival (PFS) and overall survival (OS) after treatment were 2.1 months and 9.6 months, respectively, indicating that while the treatment is safe, further studies are needed to assess its efficacy in improving patient outcomes.
Phase I trial of intracerebral convection-enhanced delivery of carboplatin for treatment of recurrent high-grade gliomas.Wang, JL., Barth, RF., Cavaliere, R., et al.[2021]

References

Phase I study of intracarotid administration of carboplatin. [2019]
Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates. [2021]
Phase I trial of intracerebral convection-enhanced delivery of carboplatin for treatment of recurrent high-grade gliomas. [2021]
Effectiveness of adjuvant carboplatin-based chemotherapy compared to cisplatin in non-small cell lung cancer. [2019]
A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung. [2013]
Clinical features and management of carboplatin-related hypersensitivity reactions in pediatric low-grade glioma. [2021]
A phase 1 study of vinblastine in combination with carboplatin for children with low-grade gliomas: a Children's Oncology Group phase 1 consortium study. [2021]
Phase II study of carboplatin in patients with nonresected lung cancer. Japan Cooperative Oncology Group on Lung Cancer. [2019]
[Brain metastases of non small cell lung cancers: systemic treatments]. [2018]
10.United Statespubmed.ncbi.nlm.nih.gov
Combined intraarterial and systemic chemotherapy for intracerebral tumors. [2019]
11.United Statespubmed.ncbi.nlm.nih.gov
Single-agent chemotherapy of brain tumors. A five-year review. [2019]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security